France Attention Deficit Hyperactivity Disorder Therapeutic Market Report 2022 to 2030

France ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

$ 3999

France's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $813 Mn in 2022 to $1,345 Mn in 2030 with a CAGR of 6.5% for the year 2022-30. The increased prevalence of ADHD in France and rising investments in mental health services are the major market drivers for the growth of the market. The France ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Novasep, Poxel, and Adlon Therapeutics are the key players in the market.

ID: IN10FRPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Parul Choudhary

Buy Now

France Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The France Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $813 Mn in 2022 and is projected to reach $1,345 Mn in 2030, exhibiting a CAGR of 6.5% during the forecast period. France's Gross Domestic Product (GDP) included 11.2% of healthcare spending. This is a little bit more than the OECD's average expenditure, which in the same year was 8.8% of GDP. In 2022, France spent about $278.12 Bn on healthcare, with about 76% of that cost coming from public funds like the national health insurance scheme. Individual out-of-pocket expenses made up about 8% of total healthcare spending, while commercial health insurance made up about 14% of the total. All citizens of France have access to healthcare facilities under the country's universal health coverage scheme, regardless of their financial or social standing. The foundation of the French healthcare system is a combination of insurance plans and state and private healthcare providers.

ADHD (attention deficit hyperactivity disorder) affects about 5% of children and is frequently present in adults (up to 80% of the time). With heredity playing a part in ADHD, up to 3.5% of adults may have the disorder, with rates much greater in parents of children who have been diagnosed. According to the most recent study that is available, the prevalence rate for children aged 6 to 12 in France varies from 3.5% to 5.6%. Furthermore, it determines that 3.48% of kids between the ages of 6 and 12 receive psychostimulant therapy.

There are currently no neurological markers, genetic markers, or biological tests to detect or support the diagnosis of hyperactivity, despite decades of intensive study. As a result, only behavioral symptoms—namely, an attention deficiency with or without motor impulsivity and hyperactivity—are evaluated in the description of ADHD. Due to this, there is a considerable worldwide discussion surrounding the prevalence of ADHD. Since 1995, methylphenidate has been authorized for the therapy of ADHD in France. Up until 2002, the number of minors receiving prescriptions was very low, but after that, it increased dramatically, by 11% annually. In 2013, about 0.5% of French children and adolescents got at least one medication. Therefore, according to the advocates of this medication, ADHD is not properly recognized or managed in France.

france attention deficit hyperactivity disorder market analysis

Market Dynamics

Market Growth Drivers

ADHD is becoming more common everywhere, including in France. In children aged 6 to 17 in France, the prevalence of ADHD was calculated to be around 3.5%, according to research that was published in the journal European Child & Adolescent Psychiatry. The demand for ADHD therapeutics in France is anticipated to increase as a result of this increasing prevalence.

Improvements in ADHD therapeutics have been made due to ongoing study and development. This covers the development of novel medications as well as non-pharmacological therapies like cognitive behavioral therapy. The France ADHD therapeutics market is anticipated to expand as a result of these developments.

There will probably be more money invested in mental health services, including ADHD treatment, as healthcare costs rise in France. The market for ADHD therapeutics in France is anticipated to expand as a result.

Market Restraints

In some regions, there is still a shortage of qualified mental health professionals despite the French government's attempts to increase access to mental health services. This may restrict the accessibility and supply of ADHD therapeutics in some areas, slowing the France ADHD therapeutics market's expansion. Despite increased knowledge of ADHD, there is still some stigma attached to the disorder. Due to the underdiagnosis and undertreatment of ADHD, the market for ADHD therapeutics in France may not expand as quickly as it might otherwise.

Competitive Landscape

Key Players

ENYO Pharma (FRA)
Laboratoire Aguettant (FRA)
AddiPsy (FRA)
Novasep (FRA)
Poxel (FRA)
Adlon Therapeutics
Amnel Pharmaceuticals
Aytu Biopharma
American Brivision
Cingulate
Eli Lilly
GSK
Johnson & Johnson

Healthcare Policies and Regulatory Landscape

The French National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament et des Produits de Santé or ANSM) is the regulatory authority in charge of overseeing pharmaceuticals in France. The French Ministry of Health oversees ANSM, a public organization tasked with assessing, regulating, and maintaining the safety, efficacy, and quality of pharmaceuticals, medical equipment, and cosmetics. Additionally, the agency releases specialized reports like the Annual Report on the State of Health in France and one for EU citizens who use the French healthcare system. The French medicines agency is also in charge of overseeing patient-involved clinical studies conducted in France, early access programs, and the reimbursement process for novel medications. The ANSM is involved in both the importation of medicines into France and pharmacovigilance activities, which include collecting and analyzing any data on adverse effects on patients' health associated with the use of medications and vaccines the agency has approved.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine
- Others
Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine

By Age Group (Revenue, USD Billion):

Pediatric And Adolescent
Adult

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Speciality Clinics
Retail Pharmacies
e-Commerce

By Psychotherapy (Revenue, USD Billion):

Behavior Therapy
Cognitive Behavioral Therapy
Interpersonal Psychotherapy
Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.